Anesiva über 85 % Verlust aber im Dezember eine neue Chance - 500 Beiträge pro Seite
eröffnet am 12.11.08 21:49:48 von
neuester Beitrag 17.12.08 22:58:21 von
neuester Beitrag 17.12.08 22:58:21 von
Beiträge: 6
ID: 1.146.044
ID: 1.146.044
Aufrufe heute: 0
Gesamt: 2.552
Gesamt: 2.552
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 24 Minuten | 879 | |
| vor 9 Minuten | 642 | |
| gestern 23:17 | 417 | |
| vor 35 Minuten | 405 | |
| gestern 21:23 | 348 | |
| vor 1 Stunde | 317 | |
| vor 45 Minuten | 304 | |
| gestern 22:29 | 279 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.703,00 | +0,24 | 90 | |||
| 2. | 2. | 10,350 | +0,19 | 70 | |||
| 3. | 3. | 9,5425 | +0,26 | 59 | |||
| 4. | 4. | 180,11 | -3,48 | 55 | |||
| 5. | 5. | 6,3660 | +0,11 | 52 | |||
| 6. | 6. | 15,700 | +5,30 | 49 | |||
| 7. | 7. | 102,30 | +11,11 | 48 | |||
| 8. | 8. | 2.364,22 | -0,61 | 37 |
Feedback
Ein kleinen Zock ?? ...
30 Cent sollten möglich sein .....
Anesiva kills sole marketed drug, cuts staff, reports other problems
San Francisco Business Times
Anesiva Inc.’s highly touted pain drug Adlea failed a late-stage clinical trial and the company will stop making its sole approved pain drug, Zingo, due to manufacturing problems and limited sales.
The South San Francisco company (NASDAQ: ANSV), which cut about 25 jobs in early September, said it will reduce staff to about 15. It also said it will repay about $20.9 million from a September loan and complete a restructuring plan by the end of the year.
Earlier this year, Anesiva had 123 employees.
“These are difficult but necessary decisions that set a new foundation upon which to rebuild value for Anesiva’s stockholders,” President and CEO Michael Kranda said in a press release.
Kranda joined Anesiva in mid-June, following the departure of John McLaughlin. (McLaughlin last week was named as the CEO of PDL BioPharma Inc. (NASDAQ: PDLI) following that company’s planned spinoff of its biotech assets yet this year.)
Nine-year-old Anesiva said the Phase III trial of Adlea to reduce pain following bunionectomy surgery failed compared with a placebo to control pain at four to 32 hours after surgery. It did, however, work at four to 48 hours after surgery and reduced opioid use over the four- to 32-hour period, the company said.
Adlea had been touted by analysts tracking the company as a potential blockbuster drug with sales of $1 billion.
Results from a Phase III trial for Adlea in total knee replacement will be announced in December.
With Zingo, which was approved by the Food and Drug Administration in August 2007, Anesiva was not able to overcome nagging manufacturing problems. The company launched Zingo on June 30 — barely hitting the promised second-quarter release date — after packaging issues.
Anesiva said it will recall Zingo product in the field due to a potential non-safety related shelf-life issue found in a lot of unreleased product.
Zingo delivers a burst of sterile lidocaine powder into the skin prior to an intravenous insertion or blood draw in children ages 3 to 18.
Anesiva this summer anticipated 2008 Zingo sales of $2 million to $3 million, but analysts had predicted eventual annual sales of $200 million to $250 million.
The drug costs about $20 per application.
The company also will meet with its joint venture partner in China, Wanbang Biopharma of Suzhou, where it planned to assemble the Zingo device.
30 Cent sollten möglich sein .....
Anesiva kills sole marketed drug, cuts staff, reports other problems
San Francisco Business Times
Anesiva Inc.’s highly touted pain drug Adlea failed a late-stage clinical trial and the company will stop making its sole approved pain drug, Zingo, due to manufacturing problems and limited sales.
The South San Francisco company (NASDAQ: ANSV), which cut about 25 jobs in early September, said it will reduce staff to about 15. It also said it will repay about $20.9 million from a September loan and complete a restructuring plan by the end of the year.
Earlier this year, Anesiva had 123 employees.
“These are difficult but necessary decisions that set a new foundation upon which to rebuild value for Anesiva’s stockholders,” President and CEO Michael Kranda said in a press release.
Kranda joined Anesiva in mid-June, following the departure of John McLaughlin. (McLaughlin last week was named as the CEO of PDL BioPharma Inc. (NASDAQ: PDLI) following that company’s planned spinoff of its biotech assets yet this year.)
Nine-year-old Anesiva said the Phase III trial of Adlea to reduce pain following bunionectomy surgery failed compared with a placebo to control pain at four to 32 hours after surgery. It did, however, work at four to 48 hours after surgery and reduced opioid use over the four- to 32-hour period, the company said.
Adlea had been touted by analysts tracking the company as a potential blockbuster drug with sales of $1 billion.
Results from a Phase III trial for Adlea in total knee replacement will be announced in December.
With Zingo, which was approved by the Food and Drug Administration in August 2007, Anesiva was not able to overcome nagging manufacturing problems. The company launched Zingo on June 30 — barely hitting the promised second-quarter release date — after packaging issues.
Anesiva said it will recall Zingo product in the field due to a potential non-safety related shelf-life issue found in a lot of unreleased product.
Zingo delivers a burst of sterile lidocaine powder into the skin prior to an intravenous insertion or blood draw in children ages 3 to 18.
Anesiva this summer anticipated 2008 Zingo sales of $2 million to $3 million, but analysts had predicted eventual annual sales of $200 million to $250 million.
The drug costs about $20 per application.
The company also will meet with its joint venture partner in China, Wanbang Biopharma of Suzhou, where it planned to assemble the Zingo device.
wie schauts jetzt in den nächsten tagen aus,gibts veränderungen??
gruss
gruss
Antwort auf Beitrag Nr.: 36.118.188 von therock1 am 30.11.08 10:26:10Schwer zu sagen ...
Das Volumen ist leider sehr niedrig...eher derzeit von der Seitenlinie
anschauen und auf neue News warten, bevor man einen Einstieg wagt..
Das Volumen ist leider sehr niedrig...eher derzeit von der Seitenlinie
anschauen und auf neue News warten, bevor man einen Einstieg wagt..
Antwort auf Beitrag Nr.: 36.119.428 von Biotechspezialx am 30.11.08 18:04:58Upss...
Sollte da schon was durch gesickert sein??????
Anesiva, Inc.
(NasdaqGM: ANSV)
Last Trade: 0.0899
Trade Time: 2:15PM ET
Change: Up 0.0200 (+28.61%)
Sollte da schon was durch gesickert sein??????
Anesiva, Inc.
(NasdaqGM: ANSV)
Last Trade: 0.0899
Trade Time: 2:15PM ET
Change: Up 0.0200 (+28.61%)
Trading Spotlight
hallo,
meint ihr da geht morgen wieder was? oder war das ein einmaliger großer anstieg?
meint ihr da geht morgen wieder was? oder war das ein einmaliger großer anstieg?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 90 | ||
| 70 | ||
| 59 | ||
| 55 | ||
| 52 | ||
| 49 | ||
| 48 | ||
| 37 | ||
| 35 | ||
| 29 |
| Wertpapier | Beiträge | |
|---|---|---|
| 26 | ||
| 25 | ||
| 25 | ||
| 25 | ||
| 23 | ||
| 23 | ||
| 22 | ||
| 22 | ||
| 21 | ||
| 20 |
